Earnings Miss: Blue Jet Healthcare Limited Missed EPS By 35% And Analysts Are Revising Their Forecasts

The analysts might have been a bit too bullish on Blue Jet Healthcare Limited (NSE:BLUEJET), given that the company fell short of expectations when it released its quarterly results last week. Unfortunately, Blue Jet Healthcare delivered a serious earnings miss. Revenues of ₹1.9b were 18% below expectations, and statutory earnings per share of ₹2.32 missed estimates by 35%. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NSEI:BLUEJET Earnings and Revenue Growth February 18th 2026 Taking into account the latest results, the consensus forecast from Blue Jet Healthcare's eight analysts is for revenues of ₹13.1b in 2027. This reflects a substantial 25% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 6.9% to ₹18.09. Before this earnings report, the analysts had been forecasting revenues of ₹14.8b and earnings per share (EPS) of ₹22.52 in 2027. It looks like sentiment has declined substantially in the aftermath of these results, with a real cut to revenue estimates and a substantial drop in earnings per share numbers as well. View our latest analysis for Blue Jet Healthcare The consensus price target fell 30% to ₹499, with the weaker earnings outlook clearly leading valuation estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Blue Jet Healthcare at ₹835 per share, while the most bearish prices it at ₹330. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Blue Jet Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 16% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Blue Jet Healthcare. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Blue Jet Healthcare going out to 2028, and you can see them free on our platform here. You can also see our analysis of Blue Jet Healthcare's Board and CEO remuneration and experience, and whether company insiders have been buying stock. Valuation is complex, but we're here to simplify it.Discover if Blue Jet Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free Analysis